Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
about
Neurophysiological biomarkers for Lewy body dementiasHandwriting as a marker for PD progression: a shift in paradigmDifferential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's diseaseSpecific changes of serum proteins in Parkinson's disease patientsDiagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human seraMetabolomics and the search for biomarkers in Parkinson's diseaseIcariin reduces α-synuclein over-expression by promoting α-synuclein degradation.Iron and Oxidative Stress in Parkinson's Disease: An Observational Study of Injury Biomarkers.Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors.Animal models of the non-motor features of Parkinson's disease.Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's diseaseObjective biomarkers of balance and gait for Parkinson's disease using body-worn sensors.Increased Rab35 expression is a potential biomarker and implicated in the pathogenesis of Parkinson's disease.Oxidative stress in genetic mouse models of Parkinson's disease.Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.Neuropathobiology of non-motor symptoms in Parkinson disease.Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Linking neuroimaging signals to behavioral responses in single cases: Challenges and opportunities.Assessment of brain metabolite correlates of adeno-associated virus-mediated over-expression of human alpha-synuclein in cortical neurons by in vivo (1) H-MR spectroscopy at 9.4 T.Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders.Management of Psychosis in Parkinson's Disease: Emphasizing Clinical Subtypes and Pathophysiological Mechanisms of the Condition.Low-Intensity Ultrasound Decreases α-Synuclein Aggregation via Attenuation of Mitochondrial Reactive Oxygen Species in MPP(+)-Treated PC12 Cells.Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.Uric acid relates to dopamine transporter availability in Parkinson's disease.3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis.Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease.[Personalised medicine. Aims and challenges].Protective Effect of Glucosinolates Hydrolytic Products in Neurodegenerative Diseases (NDDs).
P2860
Q26800048-7DC159EC-C5CA-43AC-9F72-69A2E6B2844AQ28087390-C55C18A1-5146-41A6-B9F0-2FC410AF934BQ28384168-B57796BB-56D3-45AE-A81A-F64DFF051F7DQ28538260-999BDBF0-41F4-48C8-9FC9-7C3FE409311FQ28731824-0928C503-B450-4668-8276-B84CBA67850DQ30410511-42D31268-EF42-47D3-9430-FEE1346D2DA7Q35849000-7BD718B5-8AEC-4309-9D21-DD2052C4C514Q35889862-0124E7DA-8042-414D-9DED-50A5783C6C1DQ35953962-A70651E6-B677-4742-B05B-9E6A5A83C4C0Q36235578-0CE2726A-77DB-45FB-9A61-6FAA0125577DQ36457448-AC1A1450-13C8-441E-82F0-EBE64A73514FQ37590703-157E4D77-EC58-43C8-A8F4-FA8AA0881B4CQ37688034-4095DB07-7EBC-4B0C-9251-EABBC3241750Q38029327-E683E426-9315-4123-ACF1-CB09057E731FQ38247307-DB88C272-D0BC-4FB8-B179-92DA6A6DD04AQ38325601-75A7FBB8-0193-408C-B1DA-F4926CB5D0BCQ38481481-A19D9805-0F41-4E92-A4DC-CD359F272521Q38634768-07B670F3-0A19-4F57-8F28-F30F6CCAD2E7Q38636630-78EB674E-385D-43D0-A229-DDD879F6A640Q38817013-A39D8B0C-39AE-459B-B1CC-14328155454AQ40061455-64EAE9AE-F931-4CCA-AAF9-02F597B0DA61Q41597801-3054A818-8576-41CC-B778-5F6FD4DD8533Q43375910-73A42A05-E007-45BF-9C89-9C56CFCBF2A7Q46480688-871A7F70-FE31-435B-B1AE-F6D5FB8F7C14Q47316774-D677ABD3-F0F0-4CE0-AF87-91F162B8D847Q47587631-47576005-31DA-4089-A0C7-85E531F596C3Q47627884-86FF5CBB-6C59-4281-BD97-25F74690BA00Q50607607-1506E079-0BF5-4842-A798-5E98A4C4D689Q50732857-F4DCCDBF-9757-4C73-8332-6F63E452776BQ51761574-08CE952E-D743-46E2-B143-4857F98D239BQ54678688-505B52E1-8E7F-479A-939B-F969E42D4402Q55283127-68FC00DB-0C69-41AE-AE0A-73458EB81FD2
P2860
Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Biomarker candidates of neurod ...... disease-modifying therapeutics
@ast
Biomarker candidates of neurod ...... disease-modifying therapeutics
@en
type
label
Biomarker candidates of neurod ...... disease-modifying therapeutics
@ast
Biomarker candidates of neurod ...... disease-modifying therapeutics
@en
altLabel
Biomarker candidates of neurod ...... disease-modifying therapeutics
@en
prefLabel
Biomarker candidates of neurod ...... disease-modifying therapeutics
@ast
Biomarker candidates of neurod ...... disease-modifying therapeutics
@en
P2093
P2860
P50
P921
P1476
Biomarker candidates of neurod ...... disease-modifying therapeutics
@en
P2093
Albrecht Stöffler
Johannes Streffer
Karl Broich
Lucas Rems
Manfred Gerlach
Peter Riederer
Torsten Reum
P2860
P2888
P356
10.1007/S00702-011-0682-X
P577
2011-07-14T00:00:00Z
2012-01-01T00:00:00Z